title: Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells.
abstract: Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly activates autochthonous, tumor-resident CD8(+) T cells.
authors.affiliation: TriMod Therapeutics; Dublin, Ireland.
authors.forename: Jan
authors.initials: J
authors.lastname: Emmerich
authors.forename: John B
authors.initials: JB
authors.lastname: Mumm
authors.forename: Martin
authors.initials: M
authors.lastname: Oft